The first-party data opportunity

The pharma industry has embraced the digital revolution and with that the opportunity to use more readily available data. However, effective digital engagement only works if first-party data (information a company collects directly from its customers and owns) is collected and subsequently used properly.

An article in Pharmaceutical Executive highlights that using digital channels without capturing first-party data is a missed opportunity for pharma. However, it also emphasises the importance of pharma being aware of growing data compliance and privacy restrictions, such as the loss of third-party data more traditionally collected by marketers.

To avoid reliance on data which is outside of our control, first-party data offers a significant opportunity to customise our approach, not only to what data we collect but how we then use it to inform our communication with HCPs.

Tangent90 enable pharma to share copyright ePrint content which helps drive engagement with HCPs. This content engagement provides another source of first-party data that via detailed analytics allows pharma to fully understand how ePrint content is consumed and as a result, optimise their ongoing approach.

As a Silver Technology Partner of Veeva Systems, we help pharma close the loop by feeding the data collected when sharing scientific content, back into Veeva CRM. Our market-leading SaaS solutions provide additional data points that help pharma build a complete picture of their target audience. This first-party data enables marketers to see what ePrint content an HCP has engaged with, as well as which channels they prefer, helping pharma customise their approach. This information can then be passed on to the sales reps so that they can better understand the HCP needs and optimise each engagement opportunity.

In conclusion, pharma must place a higher value on the interaction data it collects. The additional insights that our solutions provide will help better inform pharma about ongoing HCP engagement, empowering them to further customise their approach and improve outcomes.

To find out more about how Tangent90 can support you to manage your scientific content distribution, please contact us at hello@tangent90.com.

Related news

HCP access

Taking advantage of the HCP access rebound

The latest Veeva Pulse Field Trends Report is out and it discusses the change in access to HCPs. Even pre-pandemic, face-to-face meetings were in decline but the report highlights that this has bounced back, and some. The figure now sits at 60% across all specialities but what is clear is that how interaction takes place has changed.

Marketing insight

Harnessing data-driven HCP engagement

Whether it’s via email, from a congress booth, or a website, we share content with our target audience constantly. For pharma, this content can be the difference between an HCP prescribing their drug or not. It is, therefore, important to understand what happens to that content after the initial interaction with the HCP.

Congress

Next-level engagement at congress

Around 40% of congresses are now operating a hybrid format therefore optimising the whole experience has become a priority, from the initial transaction to providing measurable outcomes – it requires a complete organisational approach.

Scroll to Top

Book A Demo

We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.